SPHK2 and colorectal carcinoma: Integrated analysis of clinical cohort data revealed that CRC patients with elevated microbial SphK2 activity exhibited superior clinical outcomes following Capecitabine plus Nivolumab therapy, including significantly prolonged DFS and OS.